Chordate Medical will exhibit at the Dreiländertagung Kopfschmerz congress in Switzerland from April 25th to 27th. The congress is jointly organized by specialist associations from Germany, Switzerland, and Austria.
“It’s an excellent opportunity for us to introduce Ozilia and inform a large number of migraine and headache specialists from three significant European markets all at once,” says Anders Weilant, CEO of Chordate.
The congress will bring together headache specialists and neurologists to discuss and present the latest developments in migraine treatment, with neuromodulation being one of the topics on the agenda.
“In addition to raising awareness of Ozilia among potential investors and buyers of the company, it’s important that we continue to engage with the profession in various markets. Interest in neuromodulation as a treatment technique for migraine among specialists and neurologists is growing, and Ozilia is a unique and new treatment option that an increasing number is evaluating.”
